Fate Therapeutics (FATE) Misses Q3 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics (FATE) ASH Abstracts 'Underappreciated' - BMO
November 2, 2017 7:58 AM EDTBMO Capital analyst Do Kim reiterated an Outperform rating and $7 price target on Fate Therapeutics (NASDAQ: FATE) saying SITC and ASH data could driver shares.
Kim believes initial ProTmune Phase I data, released in ASH abstracts, were underappreciated, as the early results... More
